Full Press Release Details
Celsus Therapeutics Announces $12.5 Million Private Placement
NEW YORK, NY AND LONDON, UK, September
19, 2013 -- Celsus Therapeutics (OTCQB: CLSXY), an emerging growth, development-stage biotechnology company, announced today that
it has entered into a securities purchase agreement for a private placement financing with a select group of fundamental institutional
healthcare investors. Upon the closing of the transaction, Celsus Therapeutics will receive gross proceeds of approximately $12.5
million from the sale of approximately 22 million ordinary shares at a price of $0.57 per share. The private placement is expected
to close on or about September 24, 2013 and is subject to the satisfaction of customary closing conditions.
This press release shall not constitute
an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any
jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities
laws of any such jurisdiction.
The securities sold in the private placement
have not been registered under the Securities Act of 1933, as amended, or state securities laws and may not be offered or sold
in the United States absent registration with the Securities and Exchange Commission ("SEC") or an applicable exemption
from such registration requirements. Celsus Therapeutics has agreed to file a registration statement with the SEC covering the
resale of the ordinary shares sold in the private placement.
About MFAIDs (Multi-Functional, Anti-Inflammatory
Celsus Therapeutics is developing a platform
of first-in-class, synthetic, non-steroidal anti-inflammatory drugs. They are designed to inhibit extracellular secretory phospholipase
A2 (sPLA2), a catalytic enzyme responsible for initiating the inflammatory cascade through the production
of arachidonic acid from membrane-associated phospholipids, specifically at the cell surface. MFAIDs can inhibit all sPLA2
isomers without disrupting cytoplasmic phospholipase A2 (cPLA2), a crucial homeostatic enzyme within cells.
MDAIDS also enrich cell surface glycosaminoglycans, protecting cells from exposure to oxygen radicals and certain cytokines.
About MRX-6 - Dermatitis
MRX-6 is an MFAID topical cream treatment
under development for treating skin inflammatory disorders, specifically allergic contact dermatitis and atopic dermatitis, also
known as eczema. ACD and atopic dermatitis usually caused by environment allergens.
About Celsus Therapeutics Plc.
Therapeutics is an emerging clinical stage company focused on the development of a new class of non-steroidal, synthetic anti-inflammatory
drugs termed Multi-Functional Anti-Inflammatory Drugs or MFAIDs. Celsus's MFAIDs represent a new therapeutic platform for
the treatment of a broad array of inflammatory diseases, such as allergies and autoimmune diseases. Presently, the Company has
two lead drug candidates in its clinical pipeline, MRX-6, a topical cream for contact dermatitis and MRX-4, a nasal spray for treating
allergic rhinitis (hay fever). Other potential treatments in preclinical development include OPX-1 for ocular inflammation, CFX-1
for cystic fibrosis, and MRX-5 for inflammatory bowel disease.
FORWARD-LOOKING STATEMENTS - This
press release contains "forward-looking statements" that involve known and unknown risks, uncertainties and other factors
that may cause our actual results, performance or achievements to be materially different from any future results, performance
or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements
by terms including "anticipates," "believes," "could," "estimates," "expects,"
"intends," "may," "plans," "potential," "predicts," "projects," "should,"
"will," "would," "hope," "look forward" and similar expressions intended to identify forward-looking
statements. Forward-looking statements reflect our current views with respect to future events and are based on assumptions and
subject to risks and uncertainties. Our actual results may differ materially and adversely from those expressed in any forward-looking
statements as a result of various factors and uncertainties, including our ability to finance our operations, the future success
of our scientific studies, our ability to successfully develop drug candidates, the timing for starting and completing clinical
trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual
Report on Form 20-F discusses some of the important risk factors that may affect our business, results of operations and financial
condition. Unless we are required to do so under applicable laws, we do not intend to update or revise any forward-looking statements.
Investor Relations Contact